Recipient: Bonn University Hospital
Funding: GO-Bio initial conceptual phase 4 (01/10/2023 to 30/09/2024, EUR 119,904.00)

Project description:

The number of available antibody therapies is growing steadily. As a result treating physicians are increasingly faced with challenges in selecting a targeted therapy. There are avoidable costs for the healthcare system if initially selected antibody therapies do not lead to success. Against this background the project team plans to further develop the idea for an ‘Asthma Panel’ test platform for the targeted therapy of asthma. The aim is to support treating physicians in making a targeted and personalised selection of antibodies for asthma therapy. ‘Asthma Panel’ is a predictive diagnostic tool for sub-classifying people with severe asthma. The test platform combines individual patient markers from clinical, laboratory chemistry and the transcriptome (RNA molecules) and thus goes well beyond the state of research. ‘Asthma Panel’ is intended to enable cost-effective, standardised and reliable diagnosis and targeted therapies.

For the exploratory phase the interdisciplinary project team plans to further refine the concept for diagnostics. The product, IP and utilisation concept is to be further developed and the regulatory framework for medical device development clarified. The foundations for near-series pilot production, a multicentre clinical trial study and commercialisation are to be additionally created.